Print page content Print
Increase text size Decrease text size
Text Size


Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin


Spirovac VL5 helps provide producers with protection against disease caused by Campylobacter fetus (vibrio) and Leptospira (L. canicola, L. grippotyphosa, and L. icterohaemorrhagiae and L. pomona) including L. borgpetersenii serovar hardjo type hardjo-bovis. 

Collapse All
  • Uses

    Spirovac VL5 is for vaccination of healthy cattle, including pregnant cows and heifers, over four weeks of age, as an aid in preventing disease caused by Campylobacter fetus and Leptospira (L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and L. pomona, including L. borgpetersenii serovar hardjo type hardjo-bovis). In addition, it is especially recommended to prevent establishment of L. hardjo in the kidney, and thus shedding in the urine, for at least 12 months. Spirovac VL5 also prevents the establishment of L. hardjo in the genital tract and aids in preventing infection of the fetus.

    Key Features

    • Spirovac VL5 protects against leptospirosis caused by L. borgpetersenii serovar hardjo (Type: hardjo-bovis), an antigen not contained in some standard L5 vaccines.
    • Spirovac VL5 prevents hardjo-bovis bacteria from infecting the kidneys and reproductive tract, stopping transmission of disease.
    • Spirovac VL5 provides 12-month duration of immunity (DOI) against hardjo-bovis urinary shedding, which means less time and labor required, increasing peace of mind.
    • Spirovac VL5 helps prevent hardjo-bovis transmission in utero.
    • Spirovac VL5 stimulates a cell-mediated immune response, increasing its ability to protect against hardjo-bovis.
    • Spirovac VL5 helps provide strong placental and fetal protection, helping prevent long term maintenance host infections and fetal infections.
    • Spirovac VL5 is safe for use in pregnant cows, making it easy to implement whole-herd protection.
    • Spirovac VL5 helps deliver protection in calves as young as four weeks of age, helping prevent hardjo-bovis.
  •  Directions

    1. General directions: Vaccination of healthy cattle, including pregnant cows and heifers, is recommended. Shake well. Aseptically administer 5 mL subcutaneously or intramuscularly high on the side of the neck.
    2. Primary vaccination: Healthy cattle should receive two doses administered four to six weeks apart with booster doses given as necessary. When used as an aid in preventing genital or fetal infection, booster doses should be completed at least two weeks prior to breeding. Primary vaccination with this product in calves from four weeks of age with a second dose four to six weeks later will prevent infection, colonization and subsequent shedding of hardjo-bovis, a source of further infection in the herd.
    3. Revaccination: Annual revaccination with a single dose is recommended. Include all bulls in programs of vaccination. As part of normal biosecurity procedures, all replacement animals should begin a two-dose course of vaccination upon arrival.
    4. Good animal husbandry and herd health management practices should be employed.


    10- and 50-dose vials

  • Precautions

    1. Store away from light at 2° - 7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
    2. Use entire contents when first opened.
    3. Sterilized syringes and needles should be used to administer this vaccine.
    4. Do not vaccinate within 21 days before slaughter.
    5. Occasional hypersensitivity reactions may occur up to 18 hours postvaccination. Owners should be advised to observe animals during this period. While this event appears to be rare overall, dairy cattle may be affected more frequently than other cattle. Animals affected may display excessive salivation, incoordination, and/or dyspnea. Animals displaying such signs should be treated immediately with epinephrine or equivalent. In nonresponsive animals, other modes of treatment should be considered.
    6. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
    7. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

    Technical inquiries should be directed to Zoetis Veterinary Services (800) 366-5288 (USA).





Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2021 Zoetis Services LLC. All rights reserved.